Investigating the combination of tyrosine kinase inhibitors and antibody-drug conjugates in HER2+ cancers
LSI Challenge: Health
This project aims to exploit targeted therapies to improve outcomes for cancers with overexpression of HER2
Image 1 - Project Team
Image 2 - Project image
Classical chemotherapies are non-specific and can cause unpleasant side-effects. Targeted therapies have revolutionised cancer treatment by focusing on targets more specific to cancer cells, reducing side-effects. The HER2 protein is one such target and is overexpressed in 15-20% of HER2+ breast cancers. Tyrosine Kinase Inhibitors (TKIs) and Antibody-Drug Conjugates (ADCs) are targeted therapies used to treat HER2+ breast cancer. There is a need to develop new treatment strategies to help patients who may stop responding to these therapies. Niall is investigating why some HER2+ breast cancers stop responding to therapy and if TKI/ADC combinations can overcome resistance to therapy.
Life Sciences Institute: "Transforming Challenges into Impact"